J.V. Platko L.C. / R.J. Co / OSI Pharmaceuticals / Ligand / Ge / Genentech / Ó 2004 Elsevier Inc. / AstraZeneca / /
Country
Japan / United States / / /
Event
Product Issues / FDA Phase / / /
IndustryTerm
active site / rst metal ion / treatment of breast cancers / cancer therapy / actual site / cancer treatment / aromatic ring systems / erbB signaling network / treatment of non-small cell lung cancer / treatment of chronic myelogenous leukemia / treatment of the chronic phase of this disorder / gene product / cleavage site / oncogene product / treatment of breast cancer / catalytic site / human cancer therapy / hydroxyl / treatment of colorectal cancer / /
MedicalCondition
neoplasms / colorectal cancer / prostate cancers / solid tumors / metastatic breast cancer / chronic phase / disorder / non-small cell lung cancer / rat hepatoma extracts / Rous sarcoma / breast cancer / cancers / tumor / congestive heart failure / breast cancers / cancer / tumors / disease / glioblastoma multiforme / nervous disorders / Chronic / human cancer / diabetes / Rous sarcoma virus / pancreatic cancers / non-small cell lung cancers / squamous cell cancers / invasive breast cancer / myelogenous leukemia / lung cancer / diseases / chronic myelogenous leukemia / delayed tumor / primary brain neoplasms / HER2 overexpressing breast cancer / A431 epidermoid carcinoma / disorders / granulosa cell tumors / /
Federal Drug Administration / Robert Roskoski Jr.* Department of Biochemistry and Molecular Biology / Louisiana State University Health Sciences Center / IMC / United States Food and Drug Administration / /
Person
D.W. Denney Jr. / N. Whittle / M. Kofler / Stanley Cohen / Nat / B.M. Sefton / How / H. Fuchs / V / J. Schlessinger / T.P. Garrett / P.A. Hoyne / S. Cho / R. Roskoski Jr. / S. Sudarsanam / Oncogenic / H.S. Cho / Robert Roskoski Jr. / /
BBRC Biochemical and Biophysical Research Communications–11 www.elsevier.com/locate/ybbrc Breakthroughs and Views